1. Home
  2. IIIV vs SABS Comparison

IIIV vs SABS Comparison

Compare IIIV & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i3 Verticals Inc.

IIIV

i3 Verticals Inc.

N/A

Current Price

$18.98

Market Cap

304.5M

Sector

Technology

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.01

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IIIV
SABS
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
304.5M
293.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
IIIV
SABS
Price
$18.98
$3.01
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
★ $25.50
$11.64
AVG Volume (30 Days)
283.3K
★ 656.9K
Earning Date
11-17-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 78.53
EPS
★ 0.24
N/A
Revenue
N/A
N/A
Revenue This Year
$2.13
N/A
Revenue Next Year
$4.98
N/A
P/E Ratio
$79.25
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.63
$2.44
52 Week High
$30.09
$5.15

Technical Indicators

Market Signals
Indicator
IIIV
SABS
Relative Strength Index (RSI) 69.55 46.84
Support Level $18.47 $2.44
Resistance Level $23.29 $4.06
Average True Range (ATR) 0.60 0.24
MACD 0.20 0.03
Stochastic Oscillator 79.65 48.60

Price Performance

Historical Comparison
IIIV
SABS

About IIIV i3 Verticals Inc.

i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: